February 9, 2026
TempraMed Technologies Ltd.
ISIN: CA88024B1022
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members Vancouver, BC – February 6, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the...
Read more >>TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce...
Read more >TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled...
Read more >TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
- Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction - Turkey is one of...
Read more >TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
- Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz - Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more- Strategic agreement supports TempraMed’s global shift...
Read more >